$16.780
+0.601 (+3.58%)At close
Technical Sentiment
Overall Consensus
Technical Analysis Consensus
Moving Average Consensus
Scribe Therapeutics Inc. Common Stock (SCTX) Moving Averages Convergence Divergence (MACD) indicator is -1.68, suggesting SCTX is Sell.
Scribe Therapeutics Inc. Common Stock (SCTX) 20-Day simple moving average is 18.20, while Scribe Therapeutics Inc. Common Stock (SCTX) share price is $—, making it Sell.
Scribe Therapeutics Inc. Common Stock (SCTX) 60-Day simple moving average is 23.83, while Scribe Therapeutics Inc. Common Stock (SCTX) share price is $—, making it Sell.
Technical Analysis for SCTX
AI Technical SCTXAs of 2026-11-02, the technical board for Scribe Therapeutics Inc. Common Stock (SCTX) reads sell: 2 indicators are flashing buy, 7 are indicating sell, and 4 are neutral. Price at $16.78 sits below the 20-day, 60-day and 200-day moving averages and above the 5-day and 10-day.
Momentum readings: RSI stands at 42.603, MACD stands at -1.683 (Sell), Stochastic %K stands at 25.446, Stochastic %D stands at 20.82 and CCI stands at -52.114.
SCTX trades below the 60-day SMA (23.83) and below the 200-day SMA (23.36). Immediate resistance sits at Classic R1 18.90, then R2 21.41. Support sits at Classic S1 14.08, then S2 11.77.
Scribe Therapeutics Inc. Common Stock (SCTX) Support & Resistance Level
Scribe Therapeutics Inc. Common Stock (SCTX) Technical Indicators
2026-11-03
| Name | Value |
|---|---|
| RSI_14 | 42.603 |
| STOCHk_14_3_3 | 25.446 |
| STOCHd_14_3_3 | 20.820 |
| CCI_20 | -52.114 |
| AO_5_34 | -3.652 |
| MOM_10 | -2.520 |
| MACD_12_26_9 | -1.683 |
Scribe Therapeutics Inc. Common Stock (SCTX) Relative Strength Index (RSI_14) is 42.603, creating a Neutral signal.
Scribe Therapeutics Inc. Common Stock (SCTX) Stochastic %K is 25.446, creating a Neutral signal.
Scribe Therapeutics Inc. Common Stock (SCTX) Stochastic %D is 20.820, creating a Neutral signal.
Scribe Therapeutics Inc. Common Stock (SCTX) CCI_20 is -52.114, creating a Neutral signal.
Scribe Therapeutics Inc. Common Stock (SCTX) Awesome Oscillator (AO) is -3.652, creating a Sell signal.
Scribe Therapeutics Inc. Common Stock (SCTX) Momentum (MOM) is -2.520, creating a Sell signal.
Scribe Therapeutics Inc. Common Stock (SCTX) Moving Average Convergence Divergence (MACD) is -1.683, creating a Sell signal.
Scribe Therapeutics Inc. Common Stock (SCTX) Moving Average
2026-11-03
| Period | Simple | Signal |
|---|---|---|
| MA_5 | 16.276 | Buy |
| MA_10 | 16.385 | Buy |
| MA_20 | 18.205 | Sell |
| MA_60 | 23.833 | Sell |
| MA_200 | 23.356 | Sell |
| MA_250 | 23.356 | Sell |
Scribe Therapeutics Inc. Common Stock (SCTX) 5-Day simple moving average is 16.276, while Scribe Therapeutics Inc. Common Stock (SCTX) share price is $, making it a Buy.
Scribe Therapeutics Inc. Common Stock (SCTX) 10-Day simple moving average is 16.385, while Scribe Therapeutics Inc. Common Stock (SCTX) share price is $, making it a Buy.
Scribe Therapeutics Inc. Common Stock (SCTX) 20-Day simple moving average is 18.205, while Scribe Therapeutics Inc. Common Stock (SCTX) share price is $, making it a Sell.
Scribe Therapeutics Inc. Common Stock (SCTX) 60-Day simple moving average is 23.833, while Scribe Therapeutics Inc. Common Stock (SCTX) share price is $, making it a Sell.
Scribe Therapeutics Inc. Common Stock (SCTX) 200-Day simple moving average is 23.356, while Scribe Therapeutics Inc. Common Stock (SCTX) share price is $, making it a Sell.
Scribe Therapeutics Inc. Common Stock (SCTX) 250-Day simple moving average is 23.356, while Scribe Therapeutics Inc. Common Stock (SCTX) share price is $, making it a Sell.
Related articles
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
- AppLovin Q3 2026 Deep Dive: Beaten-Down S&P Dog Meets Axon Next-Gen Beat-and-Raise—and a $3.2B BuybaAppLovin Q3 2026: $2.185B rev (+55%), EPS $4.30 vs ~$4.03–4.04 Street, Adj EBITDA $1.842B (84%). Beat own guide $100M; Q4 $2.365–2.395B; auth +$3.2B; AH +22–24%.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.